Maxime Gauberti1, Sara Martinez De Lizarrondo1, Denis Vivien1. 1. Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM UMR-S U919, Serine Proteases and Pathophysiology of the Neurovascular Unit, GIP Cyceron, Caen, France. University of Caen Normandy, Caen, France.
Abstract
PURPOSE: The objective of the present review is to provide an overview of the available clinical and preclinical data supporting the existence of an "inflammatory penumbra" in ischemic stroke. FINDINGS: Recent data from clinical trials suggest the existence of an inflammatory area at risk, surrounding the initial ischemic lesion and secondarily infiltrated by lymphocytes, that is ultimately recruited by the ischemic core: called the "inflammatory penumbra." Experimental results support this concept. Lymphocytes, especially T-cells, enter the brain in the perilesional area in a vascular-cell adhesion molecule-1 dependent manner and participate in delayed neuronal cell death. METHODS: For writing this review, we used the more recent publications in the field, including the preclinical and clinical studies. We have also used our own experise in the field of in vivo imaging of inflammatory processes. DISCUSSION: Consequently, the intensity of the inflammatory reaction and the size of the inflammatory penumbra may vary considerably in patients, as it is the case in experimental stroke models in mice. By analogy with the ischemic penumbra of the acute phase of stroke, this secondary inflammatory penumbra represents a therapeutic opportunity during the subacute phase of stroke. Large clinical trials that target lymphocyte trafficking are currently taking place. However, to improve the benefit of such therapeutic strategies, adequate patient selection may be mandatory. CONCLUSION: In this context, innovative imaging methods including magnetic resonance imaging of adhesion molecules may contribute to noninvasively detect this inflammatory penumbra and thus to select patients eligible for such therapy.
PURPOSE: The objective of the present review is to provide an overview of the available clinical and preclinical data supporting the existence of an "inflammatory penumbra" in ischemic stroke. FINDINGS: Recent data from clinical trials suggest the existence of an inflammatory area at risk, surrounding the initial ischemic lesion and secondarily infiltrated by lymphocytes, that is ultimately recruited by the ischemic core: called the "inflammatory penumbra." Experimental results support this concept. Lymphocytes, especially T-cells, enter the brain in the perilesional area in a vascular-cell adhesion molecule-1 dependent manner and participate in delayed neuronal cell death. METHODS: For writing this review, we used the more recent publications in the field, including the preclinical and clinical studies. We have also used our own experise in the field of in vivo imaging of inflammatory processes. DISCUSSION: Consequently, the intensity of the inflammatory reaction and the size of the inflammatory penumbra may vary considerably in patients, as it is the case in experimental stroke models in mice. By analogy with the ischemic penumbra of the acute phase of stroke, this secondary inflammatory penumbra represents a therapeutic opportunity during the subacute phase of stroke. Large clinical trials that target lymphocyte trafficking are currently taking place. However, to improve the benefit of such therapeutic strategies, adequate patient selection may be mandatory. CONCLUSION: In this context, innovative imaging methods including magnetic resonance imaging of adhesion molecules may contribute to noninvasively detect this inflammatory penumbra and thus to select patients eligible for such therapy.
Entities:
Keywords:
in vivo imaging; inflammation; ischemic stroke
Authors: Arthur Liesz; Wei Zhou; Éva Mracskó; Simone Karcher; Henrike Bauer; Sönke Schwarting; Li Sun; Dunja Bruder; Sabine Stegemann; Adelheid Cerwenka; Clemens Sommer; Alexander H Dalpke; Roland Veltkamp Journal: Brain Date: 2011-03 Impact factor: 13.501
Authors: Ulrich Dirnagl; Juliane Klehmet; Johann S Braun; Hendrik Harms; Christian Meisel; Tjalf Ziemssen; Konstantin Prass; Andreas Meisel Journal: Stroke Date: 2007-02 Impact factor: 7.914
Authors: Arthur Liesz; Elisabeth Suri-Payer; Claudia Veltkamp; Henrike Doerr; Clemens Sommer; Serge Rivest; Thomas Giese; Roland Veltkamp Journal: Nat Med Date: 2009-01-25 Impact factor: 53.440
Authors: Martina A McAteer; Nicola R Sibson; Constantin von Zur Muhlen; Jurgen E Schneider; Andrew S Lowe; Nicholas Warrick; Keith M Channon; Daniel C Anthony; Robin P Choudhury Journal: Nat Med Date: 2007-09-23 Impact factor: 53.440
Authors: David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor Journal: N Engl J Med Date: 2003-01-02 Impact factor: 91.245
Authors: Eric Goulin Lippi Fernandes; Sami Ridwan; Isabell Greeve; Wolf-Rüdiger Schäbitz; Alexander Grote; Matthias Simon Journal: Front Neurol Date: 2022-05-12 Impact factor: 4.086
Authors: Ramón Iglesias-Rey; Andres da Silva-Candal; Manuel Rodríguez-Yáñez; Ana Estany-Gestal; Uxía Regueiro; Elena Maqueda; Paulo Ávila-Gómez; José Manuel Pumar; José Castillo; Tomás Sobrino; Francisco Campos; Pablo Hervella Journal: Transl Stroke Res Date: 2021-06-24 Impact factor: 6.829